Biktarvy is a once-daily pill used to treat HIV-1 infection in adults and children weighing at least 14 kg (about 31 pounds). It combines three antiviral medications into a single tablet, making it one of the most widely prescribed HIV treatments available. The FDA has approved it both for people starting HIV treatment for the first time and for those switching from another regimen.
Who Can Take Biktarvy
Biktarvy is approved for three groups of people with HIV-1. The first is anyone who has never taken HIV medication before. The second is people currently on a different HIV regimen who have an undetectable viral load (fewer than 50 copies of the virus per milliliter of blood) and want to simplify their treatment. The third is people whose current regimen isn’t fully suppressing the virus, as long as their strain of HIV hasn’t developed resistance to Biktarvy’s components.
For children, Biktarvy is available in a lower-dose tablet approved for kids aged 2 and older who weigh between 14 and 25 kg. Children under 2 or under 14 kg don’t have an approved dose. The standard adult tablet is used for anyone weighing 25 kg or more.
One important limitation: Biktarvy is not recommended for people with significantly reduced kidney function. If your kidneys are filtering below a certain threshold, your doctor will typically choose a different regimen.
How It Works
Each Biktarvy tablet contains three medications that attack HIV at two different points in its life cycle. One component blocks an enzyme called integrase, which HIV needs to insert its genetic code into your cells. The other two components block a different enzyme called reverse transcriptase, which the virus uses to copy itself. By disrupting both of these steps simultaneously, the combination makes it extremely difficult for HIV to reproduce in your body.
Biktarvy does not cure HIV. What it does is reduce the amount of virus in your blood to undetectable levels, which keeps your immune system healthy and prevents transmission to others. This requires taking the pill every day without interruption.
How Well It Works
In clinical trials of people new to HIV treatment, about 94% to 96% of participants who stayed on Biktarvy reached an undetectable viral load by 48 weeks. Real-world data on people switching to Biktarvy from other regimens shows similar results: 94% maintained viral suppression at 144 weeks (nearly three years) when researchers looked only at people who continued taking it consistently.
The drop-off between the “everyone who started” number and the “everyone who stuck with it” number is mostly explained by people who stopped the medication or were lost to follow-up, not by the drug failing. Among those who kept taking Biktarvy as directed, viral suppression remained remarkably stable over time.
Common Side Effects
Biktarvy is generally well tolerated. Through 144 weeks of clinical trials, the most common side effects were diarrhea (6%), nausea (6%), and headache (5%). Less common reactions included fatigue, abnormal dreams, dizziness, insomnia, and bloating, each affecting 1% to 3% of participants. Notably, serious side effects (grade 2 or higher) occurred in fewer than 1% of people taking the drug.
Weight and Metabolic Changes
Weight gain has been a topic of discussion with several modern HIV regimens, including Biktarvy. A study of 889 people who switched to Biktarvy found an average weight increase of just 0.7 kg (about 1.5 pounds) over 96 weeks. That’s statistically measurable but small enough that most people wouldn’t notice it.
The people most likely to gain 5% or more of their body weight were younger adults (ages 30 to 40), those who started at a normal weight, and those switching from older types of HIV medication. The same study found that cholesterol and triglyceride levels actually improved after switching to Biktarvy, with total cholesterol dropping by about 12 points and triglycerides dropping by about 30 points on average over two years.
The Hepatitis B Warning
Biktarvy carries a boxed warning, the most serious type of safety alert, related to hepatitis B. Two of Biktarvy’s components also happen to suppress the hepatitis B virus. If you’re co-infected with both HIV and hepatitis B and you stop taking Biktarvy, the hepatitis B virus can flare up severely. This doesn’t mean you can’t take Biktarvy if you have both infections. It means you should never stop it abruptly without medical guidance, and your liver function needs close monitoring for several months after any discontinuation.
Timing With Supplements and Antacids
One of the few practical complications with Biktarvy involves common over-the-counter products. Antacids containing aluminum or magnesium (like Maalox or Mylanta) interfere with absorption. If you use these, take Biktarvy at least 2 hours before or 6 hours after the antacid.
Iron and calcium supplements follow a different rule: you can take them at the same time as Biktarvy, but only if you take Biktarvy with food. The food helps ensure proper absorption even in the presence of these minerals. This timing detail is easy to overlook but matters for keeping drug levels consistent in your bloodstream.